2. Search Result
Search Result
Results for "

LX

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

1

Inhibitory Antibodies

2

Natural
Products

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-129389
    Benzyl-α-GalNAc
    5+ Cited Publications

    		 Glycosyltransferase Cancer
    Benzyl-α-GalNAc is a potent O-glycosylation inhibitor. Benzyl-α-GalNAc effectively inhibits the proliferation and activation of LX-2 cells and suppresses the expression of collagen I/III, which has good potential for investigation in liver fibrosis. Benzyl-α-GalNAc also significantly enhances the anti-tumour activity of 5-Fluorouracil (HY-90006) (e.g. pancreatic cancer) by inhibiting O-glycosylation .
    Benzyl-α-GalNAc
  • HY-15516
    Sotagliflozin
    Maximum Cited Publications
    13 Publications Verification

    LX-4211; LP-802034

    		 SGLT Metabolic Disease
    Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.
    Sotagliflozin
  • HY-13055A
    Telotristat ethyl
    4 Publications Verification

    LX1032; LX1606

    		 Tryptophan Hydroxylase Neurological Disease Cancer
    Telotristat ethyl (LX1032) is a novel, orally-delivered inhibitor of tryptophan hydroxylase that reduces serotonin production.
    Telotristat ethyl
  • HY-13055
    Telotristat etiprate
    4 Publications Verification

    LX1606 Hippurate

    		 Tryptophan Hydroxylase Neurological Disease Cancer
    Telotristat etiprate (LX1606 Hippurate) is a novel, orally-delivered inhibitor of tryptophan hydroxylase that reduces serotonin production.
    Telotristat etiprate
  • HY-134829
    BMS-986176

    LX-9211; AAK1-IN-1

    		 AAK1 Neurological Disease
    BMS-986176 (LX-9211) is a highly selective, brain-penetrant, potent AAK1 (adaptor associated kinase 1) inhibitor with an IC50 of 2 nM. BMS-986176 can be used for neurodegenerative diseases research .
    BMS-986176
  • HY-13041
    LX-1031
    1 Publications Verification

    		 Tryptophan Hydroxylase Neurological Disease
    LX-1031 is a potent, orally available tryptophan 5-hydroxylase (TPH) inhibitor that reduces serotonin (5-HT) synthesis peripherally.
    LX-1031
  • HY-12659
    LX7101
    3 Publications Verification

    		 LIM Kinase (LIMK) ROCK PKA Endocrinology
    LX7101 is a potent LIM-kinase, ROCK and PKA inhibitor with IC50s of 24 nM, 1.6 nM, 10 nM and <1 nM for LIMK1, LIMK2, ROCK2 and PKA, respectively. LX7101 proves significantly selective for LIMK2 with IC50 values of 4.3 nM and 32 nM for LIMK2 and LIMK1 at 2 μM ATP, respectively. LX7101 has the potential for ocular hypertension and associated glaucoma research .
    LX7101
  • HY-111383
    LX2343

    		Beta-secretase PI3K Amyloid-β Autophagy Neurological Disease
    LX2343 is a BACE1 enzyme inhibitor with an IC50 value of 11.43±0.36 μM. LX2343 acts as a non-ATP competitive PI3K inhibitor with an IC50 of 15.99±3.23 μM. LX2343 stimulates autophagy in its promotion of Aβ clearance.
    LX2343
  • HY-101122
    LX2761

    		SGLT GLP Receptor Metabolic Disease
    LX2761 is an orally active, dual SGLT1/SGLT2 inhibitor with IC50 values of 2.2 nM and 2.7 nM against human SGLT1 and SGLT2, respectively. LX2761 locks human SGLT1 in an outward-open conformation and blocks its putative water permeation pathway. After oral administration, LX2761 is confined exclusively to the intestinal lumen, delays intestinal glucose absorption, regulates intestinal glucose metabolism, increases cecal glucose levels, reduces cecal pH, improves glycemic control and elevates plasma total GLP-1 levels. However, LX2761 induces diarrhea in a dose-dependent manner. LX2761 can be used in diabetes-related research .
    LX2761
  • HY-14370
    LX2931

    		LPL Receptor Others Inflammation/Immunology
    LX2931 is an inhibitor of Sphingosine 1-Phosphate Lyase (S1PL). LX2931 works by increasing levels of S1P inside and outside the cell. The decrease in S1PL activity leads to a significant increase in S1P content in tissues, especially in lymphoid tissues which may lead to a restricted exodus of lymphocytes from secondary immune tissues, resulting in lymphocytopenic and immunosuppressive effects in the peripheral circulation. LX2931 can be used in research for the study of autoimmune diseases, especially rheumatoid arthritis .
    LX2931
  • HY-125980
    LX-3
    1 Publications Verification

    		 p38 MAPK Cancer
    LX-3 is a selective activator of the p38 MAPK signaling pathway and activates EGFP reporter genes that are silenced by DNA methylation, such as TNF, EGR1, LY6K, and ISG20 .
    LX-3
  • HY-156523
    TNIK&MAP4K4-IN-1

    		MAP4K Cancer
    TNIK&MAP4K4-IN-1 (compound A-39) is a dual inhibitor of TNIK and MAP4K4/HGK with IC50s of 1.29 nM and <10 nM，respectively，in human hepaticstellate cell LX-2. TNIK&MAP4K4-IN-1 can be used for cancer and fibrosis inhibition .
    TNIK&MAP4K4-IN-1
  • HY-163940
    LX1

    		Aldose Reductase Androgen Receptor Cancer
    LX1 is an anti-prostate cancer compound that targets androgen receptor (AR), AR variants and steroidogenic enzyme AKR1C3. LX1 inhibits the enzymatic activity of AKR1C3, reduces the conversion of androstenedione to testosterone and reduces the expression of AR and AR-V7 and downregulates their target genes. LX1 overcomes the resistance of tumor cells to Enzalutamide (HY-70002), and the combination with Enzalutamide (HY-70002) further inhibits tumor growth .
    LX1
  • HY-113745
    LX-6171

    		Amino acid Transporter Neurological Disease
    LX-6171 is an orally active SLC6A7 inhibitor. LX-6171 can be used to study diseases characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia .
    LX-6171
  • HY-15516R
    Sotagliflozin (Standard)

    LX-4211 (Standard); LP-802034 (Standard)

    		 SGLT Reference Standards Metabolic Disease
    Sotagliflozin (Standard) is the analytical standard of Sotagliflozin. This product is intended for research and analytical applications. Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.
    Sotagliflozin (Standard)
  • HY-143439
    LX-039

    		Estrogen Receptor/ERR Cancer
    LX-039 is a highly potent, selective and orally active estrogen receptor degrader with EC50 value of 2.29 nM. LX-039 has indole C-3 chlorine atom. LX-039 exhibits excellent mouse pharmacokinetics, low clearance, high Cmax and oral exposure. LX-039 has anti-tumor activity .
    LX-039
  • HY-179410
    Galectin-3-IN-7

    		Galectin Others
    Galectin-3-IN-7 is a selective Galectin-3 inhibitor with a Kd of 5.7 nM and shows 390-fold selectivity over Gal-1. Galectin-3-IN-7 can downregulate profibrotic signaling such as ACTA2, COL1A2, and FN1 in TGFβ-stimulated LX2 hepatic stellate cells. Galectin-3-IN-7 can be used for the research of fibrosis .
    Galectin-3-IN-7
  • HY-N14922
    Nikkomycin Lx

    		Antibiotic Bacterial Infection
    Nikkomycin Lx is an antibiotic that can be extracted from Streptomyces tendae TU901. Nikkomycin Lx exhibits anti-Candida Albicans activity and can be utilized in relevant research .
    Nikkomycin Lx
  • HY-12659B
    LX7101 monohydrochloride

    		LIM Kinase (LIMK) ROCK PKA Endocrinology
    LX7101 monohydrochloride is a potent LIM-kinase, ROCK and PKA inhibitor with IC50s of 24 nM, 1.6 nM, 10 nM and <1 nM for LIMK1, LIMK2, ROCK2 and PKA, respectively. LX7101 monohydrochloride proves significantly selective for LIMK2 with IC50 values of 4.3 nM and 32 nM for LIMK2 and LIMK1 at 2 μM ATP, respectively. LX7101 monohydrochloride has the potential for ocular hypertension and associated glaucoma research .
    LX7101 monohydrochloride
  • HY-RS14457
    TGIF2LX Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    TGIF2LX Human Pre-designed siRNA Set A contains three designed siRNAs for TGIF2LX gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TGIF2LX Human Pre-designed siRNA Set A
    TGIF2LX Human Pre-designed siRNA Set A
  • HY-149816
    Anti-inflammatory agent 41

    		Interleukin Related TNF Receptor NF-κB Inflammation/Immunology
    Anti-inflammatory agent 41 (13a) significantly inhibit lipopolysaccharide (LPS)-induced expression of the proinflammatory cytokines IL-6 and TNF-α on J774A.1, THP-1 and LX-2 cells, and inhibits the activation of the NF-κB pathway .
    Anti-inflammatory agent 41
  • HY-169927
    Ferroptosis-IN-16

    		Ferroptosis Inflammation/Immunology
    Ferroptosis-IN-16 (Compound 13l) is a specific inhibitor for ferroptosis with an EC50 of 0.7 nM and 0.9 nM in ES-2 cell and LX-2 cell. Ferroptosis-IN-16 ameliorates Acetaminophen (HY-66005)-induced acute liver injury in mouse model, and exhibits good metabolic stability in mouse liver microsomes .
    Ferroptosis-IN-16
  • HY-N14139
    Dioxamycin

    		Bacterial Infection Cancer
    Dioxamycin has anti-Gram-positive bacterial activity. Dioxamycin can inhibit Staphylococcus aureus 209P with a MIC of 3.12 μg/mL. Dioxamycin inhibits the growth of L1210, P388, IMC, LX-1 and SC-6 cells with IC50s (μg/mL) of 2.7, 1.4, 6.0, 2.0 and 2.5, respectively .
    Dioxamycin
  • HY-170543
    Dual Galectin-3/EGFR-IN-1

    		Galectin EGFR Apoptosis Inflammation/Immunology
    Dual Galectin-3/EGFR-IN-1 (Compound 29) is the dual inhibitor for Galectin-3 and EGFR with the KD of 52.29 μM and 3.31 μM. Dual Galectin-3/EGFR-IN-1 inhibits TGF-β-induced hepatic stellate cell (HSCs) activation, induces apoptosis in LX-2 cell, and exhibits anti-liver fibrotic efficacy .
    Dual Galectin-3/EGFR-IN-1
  • HY-14371
    LX2932

    		Drug Derivative LPL Receptor Inflammation/Immunology
    LX2932 is an orally active LX2931 (HY-14370) analogue and S1P/S1PR signaling axis modulator. LX2932 yields a dose-dependent decrease in circulating lymphocyte numbers. LX2932 improves collagen-induced arthritis .
    LX2932
  • HY-186207
    Demethyl-LX2761

    		SGLT Metabolic Disease
    Demethyl-LX2761 is a selective sodium-glucose cotransporter 1 (SGLT1) inhibitor. Demethyl-LX2761 can be used for the research of type 2 diabetes .
    Demethyl-LX2761
  • HY-181689
    CAII/lX-IN-1

    		Carbonic Anhydrase Others
    CAII/lX-IN-1 (compound 14 (21,301,644)) is an inhibitor belonging to the N-acyl sulfonamides class, which selectively targets Carbonic Anhydrase IX and II. The IC50 values of CAII/lX-IN-1 against hCA-IX and hCA-II are 1.2 μM and 6.7 μM, respectively, with corresponding Ki values of 0.9 and 4.8 .
    CAII/lX-IN-1
  • HY-P990834
    Anti-MAGEC2/CT10 Antibody (LX-CT10.5)

    		Transmembrane Glycoprotein Cancer
    Anti-MAGEC2/CT10 Antibody (LX-CT10.5) is a kind of mouse IgG2a κ chimeric antibody, targeting to human MAGEC2/CT10. Anti-MAGEC2/CT10 Antibody (LX-CT10.5) reacts with human melanoma-associated antigen C2 (MAGEC2), also known as CT10. Anti-MAGEC2/CT10 Antibody (LX-CT10.5) can be used for identifying MAGEC2 expressing cells in immunohistochemistry, immunofluorescence and western blot studies .
    Anti-MAGEC2/CT10 Antibody (LX-CT10.5)
  • HY-RS24681
    Zbtb16 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Zbtb16 Rat Pre-designed siRNA Set A contains three designed siRNAs for Zbtb16 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Zbtb16 Rat Pre-designed siRNA Set A
    Zbtb16 Rat Pre-designed siRNA Set A

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: